Farxiga (dapagliflozin) is a U.S. food and drug regulator approved medication. Millions of Americans live with type 2 diabetes, heart failure, and chronic kidney disease, and many require long-term daily medications and ongoing treatment to manage these conditions and reduce complications. But depending on medication and being able to afford it are two very different things and for Farxiga, that gap is wide. Patent protection, years of clinical trials, and a U.S. drug pricing system with limited negotiation power have pushed this medication beyond what many Americans can reasonably pay out of pocket. Some patients in the United States are skipping doses, splitting pills, or simply never filling their prescription not because they don’t want to get better, but because they can’t afford to. A 90-day supply of Farxiga (10 mg) costs around $1,115, nearly $4,460 a year out of pocket. You didn’t choose this diagnosis. You didn’t choose these prices. You don’t have to accept that price as your only option. This article breaks down exactly why Farxiga costs what it does from patent law to insurance formularies and walks you through real, specific strategies to lower what you pay.
What Is Farxiga?
Farxiga (dapagliflozin) is a prescription medication that is mainly used alongside diet and exercise to help treat type 2 diabetes and manage blood sugar levels. It belongs to a class of medications called SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) and SGLT2 inhibitor cost in the U.S. is among the highest of any diabetes drug class, making Farxiga one of the more expensive medications in its category.
What Makes Farxiga Different?
Farxiga does more than lower blood sugar. By helping the body remove excess sugar, salt, and water through urine, it can also help reduce the risk of certain heart and kidney complications. This broader range of benefits has made it an important treatment option not only for people with type 2 diabetes but also for some individuals with heart failure or chronic kidney disease.
What is the dosage for Farxiga?
Farxiga comes in two strengths: 5 mg and 10 mg. 5 mg is typically used to start therapy or in patients with moderate kidney impairment. 10 mg is the standard maintenance dose for most indications.
What are the most common side effects of Farxiga?
Farxiga is generally well tolerated, but you may experience some side effects. The most commonly reported include:
- Urinary tract infections (UTI)
- Vaginal Yeast Infections
- Runny or stuffy nose
More serious risks include:
- Dehydration
- Hypoglycemia
- Kidney complications
- Sexually Transmitted Infections (STIs) or Sexually Transmitted Diseases (STDs)
- Allergic reactions
Farxiga is generally not recommended during pregnancy because it may affect the developing kidneys of the unborn baby, particularly during the later stages of pregnancy. If you are pregnant, planning to become pregnant, or breastfeeding, talk to your healthcare provider about your treatment options.
Who should not use Farxiga?
Farxiga is not suitable for everyone. You should not take it if you are allergic to dapagliflozin or any of the ingredients in the medication. If you have certain kidney conditions, chronic kidney disease in particular, Farxiga may not be appropriate or may not work effectively for you. Your doctor may check your kidney function before and during treatment to make sure Farxiga is right for you.
How Much Does Farxiga Cost in the U.S. Today?
Without insurance or a prescription savings program, brand-name drug pricing for Farxiga makes it a real financial strain for many Americans to pay out of pocket. A 30-day supply of Farxiga 5 mg costs around $376.95 locally that’s approximately $4,523 a year just to stay on the lower dose. The 10 mg strength, commonly prescribed for long-term management of type 2 diabetes, heart failure, and chronic kidney disease, often costs a similar amount, although prices vary by pharmacy, insurance coverage, and discounts.
For someone managing type 2 diabetes, the medication cost of Farxiga or dealing with heart failure or chronic kidney disease on top of everyday expenses doesn’t just strain a budget. It forces choices no patient should have to make.
For many patients, these prices are simply too high but there are safer options that can bring that cost down. Many Americans who need Farxiga long-term are turning to Canadian pharmacies, where the same brand-name medication is available at a fraction of the U.S. retail price potentially saving you hundreds, or even thousands, of dollars each year.
Insurance & Medicare Costs of Farxiga
Farxiga is covered by most commercial insurance plans, but coverage alone doesn’t always mean affordable. Many plans require prior authorization for Farxiga before they’ll approve it, meaning your doctor must first submit paperwork justifying why you need it. Others enforce step therapy for Farxiga, requiring you to try and fail on a cheaper alternative before your plan will cover it at all.
Even for Medicare beneficiaries, out-of-pocket costs can add up. Research examining Medicare Part D coverage of SGLT2 inhibitors the drug class Farxiga belongs to found that despite widespread plan coverage, you could still face significant annual out-of-pocket costs for this medication. That financial gap hits hardest for older Americans on fixed incomes who depend on Farxiga every single day to protect their heart or kidneys.
Is Buying Farxiga From a Canadian Online Pharmacy Safe?
Yes, buying Farxiga from a Canadian online pharmacy can be safe when you choose a CIPA certified online pharmacy partner.
Health Canada and the U.S. food and drug regulator both recommend purchasing prescription medications only from verified websites and provide access to pharmacy professionals who can answer questions about your treatment.
As with any online purchase, it is important to verify that the pharmacy is legitimate and operates in accordance with recognized standards. CIPA-certified partners are transparent about their licensing information, require a prescription for prescription-only medications, and provide clear contact details for customer support.
Before ordering Farxiga online, take a few moments to review the pharmacy websites credentials and policies. Choosing a trusted and established pharmacy partner can help ensure that you receive authentic medication and professional pharmacy services throughout the ordering process.
Why Is Farxiga So Expensive?
The U.S. prescription drug market is characterized by high prices due to monopoly protections, patent systems, and limited price regulation, which can make medications like Farxiga expensive for patients compared to affordability in many healthcare systems globally.
Understanding what drives these costs can help explain why accessing affordable type-2 diabetes treatment has become so challenging for American patients.
Lack of Price Regulation Allows Manufacturers to Set High Prices
One of the biggest reasons Farxiga costs so much in the U.S. is the absence of government price regulation. Unlike Canada, where government agencies review and negotiate Farxiga prices to keep them affordable, American pharmaceutical companies can charge whatever the market will bear. This means patients often pay far more than necessary simply because there’s no system in place to control costs.
Patent Protection Limits Competition and Keeps Prices High
Farxiga was protected by multiple U.S. patents and U.S. food and drug regulator recognized exclusivity periods that limited generic competition for many years.The drug’s primary compound patent expired in April 2026, and the U.S. food and drug regulator has since approved the first generic Farxiga versions which could mean lower costs for you going forward. Patent and exclusivity protections can delay generic entry, which may contribute to higher brand-name drug prices while those protections remain in effect.
Research and Development Costs Are Passed Directly to Patients
Developing Farxiga required significant investment in laboratory research, clinical trials, and regulatory approvals. While these costs are real, the lack of price regulation in the U.S. means manufacturers can recoup their R&D drug costs by charging American patients premium prices, often several times what patients in other countries pay for the same medication.
Marketing and Branding Add to Your Out-of-Pocket Costs
Like many brand-name prescription medications, Farxiga has been promoted to healthcare professionals and consumers through educational and marketing campaigns. Brand-name drug manufacturers may invest heavily in pharmaceutical marketing expenses including advertising, patient support programs, and promotional activities to increase awareness of their products.. These expenses are part of the overall costs associated with bringing and maintaining a branded medication in the market, which can contribute to higher prices compared with generic alternatives when available.
The U.S. Insurance System Often Fails to Lower Patient Costs
Even with insurance, many Americans face high out-of-pocket costs for Farxiga. The complex network of insurance plans, pharmacy benefit managers, and rebate negotiations rarely translates into meaningful savings for patients. High deductibles, restrictive formularies, and tiered pricing can leave you paying hundreds of dollars, even with “good” insurance coverage.
The Result: Americans Pay More for Farxiga
These factors combine to create a system where U.S. patients consistently pay more for Farxiga than patients in countries with regulated drug pricing. The medication is the same, but the price tag isn’t, and that’s a direct result of policy choices, not market necessity.
Are Generic Versions of Farxiga Available?
Yes. Generic versions and other lower-cost alternatives to Farxiga may help make long-term treatment more affordable for many patients.
Generic dapagliflozin, the active ingredient in Farxiga, is now available in some markets and the dapagliflozin price is lower than the brand-name version, which may help reduce treatment costs. The U.S. food and drug regulator approved the first generic versions of dapagliflozin in April 2026. However, the availability and cost of generic medications can vary by pharmacy, insurance plan, and location.
While generic competition often leads to lower prices over time, some patients may still face significant out-of-pocket costs depending on their prescription drug coverage, deductibles, and copay requirements. Comparing pharmacy prices and reviewing insurance benefits can help identify the most affordable option.
How to Get Dapagliflozin for About $0.95 Per Pill From Canada?
Through a trusted prescription referral service like PrescriptionPoint.com, you can get Dapagliflozin 10 mg for 30 days for $28.50 from Canada. This translates to a savings of approximately 96% compared to your local pharmacy. That’s approximately $7,631 in annual savings. If you take dapagliflozin long term, those savings can add up quickly and may reduce the financial burden of ongoing treatment.
You can buy Dapagliflozin for as low as $0.95 per tablet online from a Canadian pharmacy through PrescriptionPoint.com
Cheaper Alternatives to Farxiga
Depending on your medical condition, treatment goals, insurance coverage, and doctor’s recommendations, several alternatives may be available. Common Farxiga alternatives include:
Jardiance (empagliflozin)
Jardiance (empagliflozin) is an SGLT2 inhibitor that helps lower blood sugar by removing excess glucose through the urine. It is often considered a leading alternative to Farxiga because both medications work similarly and may provide benefits for type 2 diabetes, heart health, and kidney function.
Many patients compare Jardiance and Farxiga because both are widely prescribed SGLT2 inhibitors used to help manage type 2 diabetes while also supporting heart and kidney health. Since these medications work in similar ways, the choice often depends on factors such as a patient’s medical history, treatment goals, potential side effects, and overall cost.
For patients seeking a more affordable option, PrescriptionPoint.com’s trusted prescription referral service may help eligible individuals access Jardiance 10 mg for as little as $23.40 for a 30-day supply. Compared to a typical U.S. pharmacy price of $422.83, that represents potential savings of approximately 95%, or nearly $4,800 per year.
You can buy Jardiance for as low as $0.78 per tablet online from a Canadian pharmacy through PrescriptionPoint.com
Invokana (canagliflozin)
Invokana (canagliflozin) is a prescription medication that helps manage type 2 diabetes and may reduce the risk of certain kidney and cardiovascular complications. It is often compared with Farxiga because both belong to the same drug class and are commonly prescribed for patients needing benefits beyond blood sugar control.
Many patients compare Invokana (canagliflozin) with other SGLT2 inhibitors, such as Jardiance and Farxiga, because these medications are commonly prescribed to help manage type 2 diabetes while also offering cardiovascular and kidney-related benefits. While they belong to the same drug class, the most appropriate option often depends on factors such as a patient’s medical history, treatment goals, side effect considerations, and cost.
For patients seeking a more affordable option, PrescriptionPoint.com’s trusted prescription referral service may help eligible individuals access Invokana 100 mg for as little as $159 for a 30-day supply. Compared to a typical U.S. pharmacy price of $718.33, that represents potential savings of approximately 78%, or more than $6,700 per year.
You can buy Invokana for as low as $5.30 per tablet online from a Canadian pharmacy through PrescriptionPoint.com
Strategies to Lower Your Farxiga Costs
There are several strategies to reduce the cost of Farxiga, but not all are equally reliable or accessible. Understanding your options can help you find a sustainable solution that works for your budget.
Patient Assistance Programs & Manufacturer Coupons
A patient assistance program for Farxiga and manufacturer coupons are designed to help reduce your out-of-pocket expenses. However, these programs are often unreliable for long-term savings. They typically have strict eligibility criteria based on income level, insurance status, or citizenship. Additionally, coupons may expire, be discontinued without notice, or only provide temporary discounts that leave you paying full price later.
Insurance Navigation
Insurance coverage can lower your cost for Farxiga, but plan details vary widely. Even with insurance, you may face high deductibles, co-pays, or find that Farxiga isn’t covered at all under your specific plan. Coverage can also change year to year, leaving you with unexpected costs. Understanding your plan helps, but it doesn’t guarantee affordable access.
Compare Pharmacy Options
Pharmacy prices for the same medication can vary, and comparing local and online pharmacy options may help you find slightly better deals. However, even the lowest U.S. pharmacy prices are often still unaffordable for many patients due to the lack of price regulation.
Get Farxiga from a Canadian Online Pharmacy
Unlike the temporary fixes and eligibility barriers of assistance programs, international and Canadian pharmacy partners like PrescriptionPoint.com offer consistently affordable prices due to Canada’s government pricing regulations and controlled markups making them the most reliable long-term solution if you’re looking to lower your medication costs.
For example, through our international pharmacy pricing, you can get Farxiga 10 mg for 30 days for $78.60, a savings of approximately 79% compared to a typical U.S. price of $376.95 at your local pharmacies, that’s approximately $3,580 in annual savings compared to your local price. These savings are consistent, available to everyone regardless of income or insurance status, and represent a reliable long-term solution for managing your type-2 diabetes affordably.
You can buy Farxiga for as low as $2.62 per tablet online from a Canadian pharmacy through PrescriptionPoint.com
Frequently Asked Questions
Is There a Farxiga Copay Card, Coupon, or any Discount?
Yes. Some patients may qualify for a Farxiga coupon, a manufacturer copay card, or pharmacy discount programs that can help reduce what you pay. However, eligibility requirements vary, and not everyone will qualify. If you don’t qualify for those discounts, using a licensed Canadian pharmacy service like PrescriptionPoint.com can help you find affordable prices for your prescription.
Does Dosage Strength Affect Cost?
Yes, It can. In the United States, prescription drug prices can vary significantly depending on the pharmacy, insurance plan, and whether you’re purchasing the 5 mg or 10 mg strength. Some patients discover that their out-of-pocket costs remain high regardless of dosage.
By comparison, prices available through licensed Canadian pharmacy services are often more consistent across strengths, with only modest differences between dosage options. Depending on your prescription and current U.S. pricing, comparing options like the Forxiga price in Canada through a licensed pharmacy service could save you hundreds of dollars a month.
What If My Insurance Doesn’t Cover Farxiga?
You can speak with your healthcare provider to appeal the coverage decision, request prior authorization, or ask about your insurance copay for Farxiga under a different plan tier or alternative treatment. Or another safe option is to go through licensed Canadian pharmacy services such as PrescriptionPoint.com, which may offer the same medication at a more affordable price and potentially reduce annual prescription costs compared with typical U.S. retail pricing.
References
- U.S. Food and Drug Administration. (2024). FDA approves first generic dapagliflozin tablets. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets
- Li, Y., Zhou, Z., Sun, X., Zhang, X., & Liu, Y. (2024). Effectiveness and safety of dapagliflozin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Therapy, 15(3), 345–362. https://pmc.ncbi.nlm.nih.gov/articles/PMC12129069/
- Singh, R., Patel, A., & Kumar, S. (2024). Dapagliflozin in heart failure: An updated evidence review. Cardiovascular Diabetology, 23(1), 112. https://pmc.ncbi.nlm.nih.gov/articles/PMC12179530/
- Drugs.com. (2025). Farxiga prices, coupons and patient assistance programs. https://www.drugs.com/price-guide/farxiga
- Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P. H., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., Fenici, P., Hammar, N., & Nauck, M. A. (2022). Outcomes associated with use of SGLT2 inhibitors in patients with type 2 diabetes: A real-world analysis. Cardiovascular Diabetology, 21(1), 32. https://pmc.ncbi.nlm.nih.gov/articles/PMC8903137/
- Cleveland Clinic. (2024). Dapagliflozin tablets: Uses & side effects. https://my.clevelandclinic.org/health/drugs/19382-dapagliflozin-tablets
- Drugs.com. (2025). Dapagliflozin: Uses, dosage, side effects. https://www.drugs.com/dapagliflozin.html
- WebMD. (2025). Farxiga (dapagliflozin): Overdose. https://www.webmd.com/drugs/farxiga-dapagliflozin#overdose
- WebMD. (2025). Farxiga (dapagliflozin): Uses, side effects & more. https://www.webmd.com/drugs/farxiga-dapagliflozin
- Drugs.com. (2025). Farxiga: Uses, dosage, side effects. https://www.drugs.com/farxiga.html
- WebMD. (2025). Farxiga (dapagliflozin): Warnings and precautions. https://www.webmd.com/drugs/farxiga-dapagliflozin#precautions
- Brown, J. D., Smith, K., & Taylor, P. (2023). Dapagliflozin for the treatment of chronic kidney disease: A review of current evidence. Kidney International Reports, 8(4), 700–711. https://pmc.ncbi.nlm.nih.gov/articles/PMC10220512/
- Chen, L., Wang, Y., Zhang, Q., & Zhao, H. (2023). Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with diabetes and chronic kidney disease. Frontiers in Endocrinology, 14, 1234567. https://pmc.ncbi.nlm.nih.gov/articles/PMC10397592/
- Bailey, C. J., Gross, J. L., Hennicken, D., Iqbal, N., Mansfield, T. A., & List, J. F. (2013). Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized controlled trial. International Journal of Clinical Practice, 67(12), 1213–1223. https://pubmed.ncbi.nlm.nih.gov/28498650/
- Kaku, K., Lee, J., Mattheus, M., Kaspers, S., George, J., Woerle, H. J., & Broedl, U. C. (2017). Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease. Cardiovascular Diabetology, 16(1), 152. https://pmc.ncbi.nlm.nih.gov/articles/PMC7563069/
- Gupta, R., Sharma, S., & Mehta, N. (2024). Cost-effectiveness of SGLT2 inhibitors in type 2 diabetes management. Journal of Health Economics and Outcomes Research, 12(2), 89–99. https://pmc.ncbi.nlm.nih.gov/articles/PMC12293934/
- Health Canada. (2019). Safe use of online pharmacies. https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html
- Ahmed, S., Khan, M., & Ali, R. (2025). Online pharmacies: Regulatory challenges and patient safety. Journal of Pharmaceutical Policy and Practice, 18(1), 45. https://pmc.ncbi.nlm.nih.gov/articles/PMC12765123/
- U.S. Food and Drug Administration. (2023). Considering an online pharmacy. https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/considering-online-pharmacy
- Almomani, B. A., Al-Saadi, T., & others. (2020). Public awareness and use of online pharmacies in different regions. Journal of Pharmaceutical Health Services Research, 11(3), 229–237. https://pmc.ncbi.nlm.nih.gov/articles/PMC7311400/
- Gallo, L. A., Wright, E. M., & Vallon, V. (2015). Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and clinical overview. Diabetes & Vascular Disease Research, 12(2), 78–89. https://pmc.ncbi.nlm.nih.gov/articles/PMC5417581/
- Santos, R., Silva, M., & Costa, J. (2023). SGLT2 inhibitors and risk of urinary tract infections: A pharmacovigilance study. Diabetes Research and Clinical Practice, 198, 110572. https://pmc.ncbi.nlm.nih.gov/articles/PMC11347552/
- Drugs.com. (2025). Farxiga vs Jardiance comparison. https://www.drugs.com/compare/farxiga-vs-jardiance
- Drugs.com. (2025). Farxiga vs Invokana comparison. https://www.drugs.com/compare/farxiga-vs-invokana
- Neal, B., Perkovic, V., Mahaffey, K. W., et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644–657. https://pmc.ncbi.nlm.nih.gov/articles/PMC5620794/
- Wiviott, S. D., Raz, I., Bonaca, M. P., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347–357. https://pubmed.ncbi.nlm.nih.gov/31569218/
- Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010). Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care, 33(10), 2217–2224. https://pmc.ncbi.nlm.nih.gov/articles/PMC4106580/
- McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2022). Dapagliflozin in patients with heart failure and mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387(12), 1089–1098. https://pmc.ncbi.nlm.nih.gov/articles/PMC9441277/
- Packer, M., Anker, S. D., Butler, J., et al. (2023). Mechanisms of benefit of SGLT2 inhibitors in heart failure. European Heart Journal, 44(2), 110–121. https://pmc.ncbi.nlm.nih.gov/articles/PMC9870667/
- Padda, I. S., Mahtani, A. U., & Parmar, M. (2025). Sodium-glucose transport 2 (SGLT2) inhibitors. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK576405/
